PTC Therapeutics registers Phase 2A trial of PTC844 in rheumatoid arthritis
The trial will test PTC844, a DHODH inhibitor, against placebo in patients with active rheumatoid arthritis, with an estimated start in August 2026.
PTC Therapeutics registered one new rheumatoid arthritis trial this week.
- A Phase 2A study titled "A Phase 2A, Proof-of-Concept, Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PTC844 in Participants With Active Rheumatoid Arthritis" (NCT07779616) was listed as not yet recruiting, with an estimated enrollment of 75 participants1 testing low and high doses of PTC844 against placebo over 12 weeks. The study is sponsored by PTC Therapeutics, with an estimated start date of 2026-08-31 and estimated primary completion of 2027-09-30.1 Primary outcomes include the number of participants with treatment-emergent adverse events through Week 16 and the change from baseline to Week 2 in dihydroorotate (DHO).1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.